IDEAYA Biosciences (IDYA) News Today $17.43 -0.01 (-0.06%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$17.42 0.00 (-0.03%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 28 at 6:00 AM | prnewswire.comEntryPoint Capital LLC Invests $377,000 in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)EntryPoint Capital LLC purchased a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,670 shares of the company's stock, valued at approximMarch 28 at 4:57 AM | marketbeat.comIDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase InhibitorMarch 26 at 6:00 AM | prnewswire.comSwiss National Bank Buys 16,500 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Swiss National Bank boosted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 149,600 shares of the company's stock after aMarch 26 at 3:25 AM | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, twelve have issuedMarch 26 at 2:23 AM | marketbeat.comCharles Schwab Investment Management Inc. Buys 23,738 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Charles Schwab Investment Management Inc. raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 712,811 shares ofMarch 20, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by AlphaQuest LLCAlphaQuest LLC trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 77.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,661 shares of the company's stock after selliMarch 17, 2025 | marketbeat.comBank of New York Mellon Corp Sells 49,932 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Bank of New York Mellon Corp reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 18.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 226,299 shares of the company's stock after selling 49,932 shares duringMarch 17, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Position Increased by Victory Capital Management Inc.Victory Capital Management Inc. raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 341,063 shares of the company's stock after buying an additional 27,8March 14, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Sets New 1-Year Low - Here's What HappenedIDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week Low - Should You Sell?March 10, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up - Time to Buy?IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up - Here's WhyMarch 8, 2025 | marketbeat.comCandriam S.C.A. Grows Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Candriam S.C.A. grew its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 14.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,071,825 shares of the company's stock after acquiring an additional 131,385 shares during the period. CanMarch 7, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery PlatformMarch 5, 2025 | msn.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Fisher Asset Management LLCFisher Asset Management LLC grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 876,599 shares of the company's stock after purchasingMarch 4, 2025 | marketbeat.comIdeaya Biosciences announces research collaboration with AttmosMarch 3, 2025 | markets.businessinsider.comIDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology TargetsMarch 3, 2025 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)March 2, 2025 | nasdaq.comIDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year Low - Should You Sell?IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low - Time to Sell?March 1, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has been given an average rating of "Moderate Buy" by the fifteen research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, twelve have asMarch 1, 2025 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)February 28, 2025 | prnewswire.comState of New Jersey Common Pension Fund D Boosts Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)State of New Jersey Common Pension Fund D boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 62.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,174 shares of the company's stock afteFebruary 23, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low - Here's WhyIDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week Low - Here's WhyFebruary 19, 2025 | marketbeat.comBrokers Issue Forecasts for IDYA FY2029 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Investment analysts at Wedbush issued their FY2029 EPS estimates for IDEAYA Biosciences in a report issued on Thursday, February 13th. Wedbush analyst R. Driscoll expects that the company will earn $1.20 per share for the year. Wedbush has aFebruary 17, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Issues Earnings ResultsIDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million.February 16, 2025 | marketbeat.comIDEAYA Biosciences' (IDYA) "Overweight" Rating Reiterated at StephensStephens reaffirmed an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday.February 15, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Fiera Capital CorpFiera Capital Corp trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 8.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,184,467 shares of the company's stock after selling 105,35February 14, 2025 | marketbeat.comIdeaya Biosciences price target lowered to $40 from $53 at OppenheimerFebruary 13, 2025 | markets.businessinsider.comIdeaya Biosciences enters additional supply pact with Gilead for IDE397February 13, 2025 | markets.businessinsider.comIDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.8% - Here's What HappenedIDEAYA Biosciences (NASDAQ:IDYA) Shares Down 4.8% - Should You Sell?February 13, 2025 | marketbeat.comIdeaya Biosciences reports Q4 EPS ($1.49), consensus (62c)February 13, 2025 | markets.businessinsider.comIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 13, 2025 | prnewswire.comIDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLCFebruary 13, 2025 | prnewswire.comIdeaya Biosciences stock hits 52-week low at $21.02February 12, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Should You Sell?IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low - Here's What HappenedFebruary 11, 2025 | marketbeat.comIDEAYA Biosciences (IDYA) Projected to Post Earnings on TuesdayIDEAYA Biosciences (NASDAQ:IDYA) will be releasing earnings before the market opens on Tuesday, February 18, Financial Modeling Prep reports.February 11, 2025 | marketbeat.comIDEAYA Biosciences Taps J.P. Morgan Exec for CFOFebruary 10, 2025 | marketwatch.comIDEAYA Biosciences appoints new CFOFebruary 10, 2025 | msn.comIDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial OfficerFebruary 10, 2025 | prnewswire.comWCM Investment Management LLC Takes $6.03 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)WCM Investment Management LLC acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 241,894 shares of the company's stock, valued at approximately $6February 10, 2025 | marketbeat.comQ1 Earnings Estimate for IDYA Issued By Leerink PartnrsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for IDEAYA Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.66) perFebruary 10, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by abrdn plcabrdn plc boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 31.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 306,723 shares of the company's stock after purchasing an additional 73,893 shares during the period. abrdn plc owned aboFebruary 9, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have received a consensus rating of "Moderate Buy" from the sixteen research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buFebruary 4, 2025 | marketbeat.comSG Americas Securities LLC Boosts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)SG Americas Securities LLC boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 444.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,486 shares of theFebruary 2, 2025 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 31, 2025 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations EventsJanuary 27, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (IDYA)January 25, 2025 | ca.finance.yahoo.comCantor Fitzgerald Comments on IDYA FY2025 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the coJanuary 22, 2025 | marketbeat.comIDEAYA Biosciences: Promising Pipeline and Strategic Growth Drive Buy RatingJanuary 22, 2025 | markets.businessinsider.comBTIG reiterates Buy on Ideaya stock, cites significant updatesJanuary 21, 2025 | msn.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Lifted by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 17.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 79,780 shares of the company's stock after acquiring an additional 12,029 shares during the period. JJanuary 21, 2025 | marketbeat.com Remove Ads Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address IDYA Media Mentions By Week IDYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼1.410.78▲Average Medical News Sentiment IDYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼46▲IDYA Articles Average Week Remove Ads Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Axsome Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News Blueprint Medicines News Krystal Biotech News Nuvalent News Cytokinetics News Verona Pharma News Grifols News Elanco Animal Health News ADMA Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IDYA Stock Free IDYA Stock Alerts